Avadel Pharmaceuticals Net Worth
Avadel Pharmaceuticals Net Worth Breakdown | AVDL |
Avadel Pharmaceuticals Net Worth Analysis
Avadel Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avadel Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avadel Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avadel Pharmaceuticals' net worth analysis. One common approach is to calculate Avadel Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avadel Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avadel Pharmaceuticals' net worth. This approach calculates the present value of Avadel Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avadel Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avadel Pharmaceuticals' net worth. This involves comparing Avadel Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avadel Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Avadel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avadel Pharmaceuticals' net worth research are outlined below:
| Avadel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Avadel Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 27.96 M. Net Loss for the year was (160.28 M) with profit before overhead, payroll, taxes, and interest of 16.59 M. | |
| Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (128.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Avadel Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Avadel Pharmaceuticals PLC Shares Up 3 percent on Nov 22 |
Avadel Pharmaceuticals Quarterly Good Will |
|
Avadel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avadel Pharmaceuticals PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avadel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Avadel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avadel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avadel Pharmaceuticals PLC backward and forwards among themselves. Avadel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Avadel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tri Locum Partners Lp | 2024-09-30 | 1.7 M | Woodline Partners Lp | 2024-06-30 | 1.5 M | Brandes Investment Partners & Co | 2024-09-30 | 1.4 M | Tang Capital Management Llc | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.1 M | Checkpoint Capital Lp | 2024-09-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-06-30 | 994.7 K | Samsara Biocapital, Llc | 2024-09-30 | 967.5 K | Hhg Plc | 2024-06-30 | 13.3 M | Polar Capital Holdings Plc | 2024-06-30 | 6.6 M |
Follow Avadel Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.27 B.Market Cap |
|
Project Avadel Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.08) | (1.03) | |
| Return On Capital Employed | (1.08) | (1.02) | |
| Return On Assets | (0.97) | (0.92) | |
| Return On Equity | (1.83) | (1.92) |
When accessing Avadel Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avadel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avadel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Avadel Pharmaceuticals' management efficiency
Avadel Pharmaceuticals has return on total asset (ROA) of (0.3445) % which means that it has lost $0.3445 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9952) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -1.03 this year. Return On Capital Employed is expected to rise to -1.02 this year. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 8.17 this year, although the value of Total Assets will most likely fall to about 134.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.09 | 1.77 | |
| Tangible Book Value Per Share | 0.88 | 1.28 | |
| Enterprise Value Over EBITDA | (7.62) | (8.00) | |
| Price Book Value Ratio | 12.90 | 13.55 | |
| Enterprise Value Multiple | (7.62) | (8.00) | |
| Price Fair Value | 12.90 | 13.55 | |
| Enterprise Value | 388.4 M | 201.8 M |
Management at Avadel Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 7.6702 | Revenue 95.1 M | Quarterly Revenue Growth 26.743 | Revenue Per Share 1.036 | Return On Equity (1.00) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avadel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avadel Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Avadel Pharmaceuticals Earnings per Share Projection vs Actual
Avadel Pharmaceuticals Corporate Management
| Gregory Davis | VP Development | Profile | |
| Richard Kim | Chief Officer | Profile | |
| Christian PharmD | Chief Affairs | Profile | |
| Steven Sullivan | VP Operations | Profile | |
| Jason Vaughn | Senior Operations | Profile | |
| Jennifer PharmD | Senior Affairs | Profile |
Already Invested in Avadel Pharmaceuticals PLC?
The danger of trading Avadel Pharmaceuticals PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avadel Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avadel Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avadel Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.